Chai Discovery said it has entered a collaboration with GSK after the drugmaker evaluated the company's artificial intelligence models for molecular design.
Under the agreement, GSK will get access to Chai's platform, including its protein folding and design models. GSK will use them for discovery work across its pipeline. Financial terms were not disclosed.
In the evaluation, Chai's models generated designs against GSK targets "zero-shot," meaning they had no target-specific training. GSK tested the designs in its own wet labs and found binders to all of the targets it tested. Chai said these results led GSK to expand the work into a broader collaboration.
"We evaluated their models across a panel of diverse targets and saw designs with strong binding affinities," said Christopher Austin, senior vice president of R&D Technologies at GSK. He said the technology complements GSK's internal models, which the company keeps retraining on its own wet-lab data.
Joshua Meier, Chai's co-founder and chief executive, said the evaluation let both teams test Chai's models against a range of therapeutic targets in the lab.
Chai builds AI models for preclinical drug discovery. The models predict and modify the interactions between molecules. Its newest model is Chai-3.
The company said the GSK deal is the latest in a series of collaborations with pharmaceutical companies that it has announced since the start of 2026.
San Francisco-based Chai was founded in 2024 by Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!